HUTCHMED (China) Ltd (STU:H7T1)
€ 15.7 0 (0%) Market Cap: 2.68 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 4.10 GF Score: 70/100

Hutchison China MediTech Limited - Special Call Transcript

Sep 30, 2019 / 12:00PM GMT
Release Date Price: €15.4 (-3.45%)
Christian Hogg
Hutchison China MediTech Limited - CEO & Executive Director

Welcome, everybody, to the ESMO conference call in which we plan to take everybody through the surufatinib SANET-ep Phase III data, along with the further information around surufatinib and neuroendocrine tumors.

What we're going to try and do today is try and get through the presentation in about 35 minutes, leaving 20, 25 minutes for Q&A at the end.

So if we go to Page #3, the agenda. I'll give a brief introduction on where surufatinib is at the moment. That will be followed by a discussion on -- of the presentation that was given at ESMO yesterday by Dr. Wei-Guo Su, our Chief Scientific Officer and main Board Director of Chi-Med. That will be followed by a presentation around the Phase Ib data for surufatinib in the U.S. by Marek Kania, our SVP and Chief Medical Officer in international, basically United States and Europe. That will be followed by a discussion on neuroendocrine tumors by Dr. James Yao, one of our key investigators. We're extremely happy and pleased that Dr. Yao could make time to join

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot